FDA Ups Recent Recalls

The US regulatory agency recalled 54 percent more drugs from the second to third quarters of 2011.

Written byBob Grant
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

FLICKR, CANDY

The US Food and Drug Administration's increased oversight of US drug manufacturing plants has led to a big jump in the number of drug products recalled in the third quarter of this year, according to a report issued by Stericycle ExpertRECALL, a company that tracks such trends. Specifically, the FDA recorded 150 recalls in the third quarter of 2011, up from 97 in the second quarter.

"The FDA has stepped up its oversight of US manufacturing plants and operations," Stericycle ExpertRECALL Vice President for Recalls Mike Rozembajgier wrote in an email to FiercePharma Manufacturing. "And with the US Government Accountability Office's recent call for the agency to intensify its efforts to track and regulate overseas pharmaceutical manufacturing, we can expect the FDA to intensify its ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies